Oncology Research Program (ORP) today announced funding awards for quality improvement initiatives in CML. The NCCN ORP will oversee these projects, with funding provided by Novartis Pharmaceuticals ...
Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...
CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...
Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced that the first patient has been enrolled in the VITAL-CML trial, w ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
The latest research on chronic myeloid leukemia (CML) presented at the 2024 American Society of Hematology 2024 Annual Meeting and Exposition is reported by Dr Jorge Cortes from Georgia Cancer Center ...
A KAIST research team has identified the real reason why anticancer drugs kill cancer cells—targeted anticancer therapies do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results